Live Breaking News & Updates on Casi Pharmaceuticals Inc
Stay updated with breaking news from Casi pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 53,100 shares, a growth of 14.7% from the April 30th total of 46,300 shares. Currently, 0.8% of the shares of the company are […] ....
HC Wainwright Comments on CASI Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:CASI) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. ....
China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. ....
CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 127,300 shares, a growth of 204.5% from the February 29th total of 41,800 shares. Based on an average trading volume of 194,700 shares, […] ....